Inclusion Criteria:
- Participants with a histologically or cytologically confirmed, advanced,
unresectable/metastatic, solid malignancy of any histology measurable by Response
Evaluation Criteria in Solid Tumors (RECIST) v1.1
- Participants who have received, been refractory to, ineligible for, or intolerant of
existing therapy(ies) known to provide clinical benefit for the condition of the
participant
- Participants with melanoma should have documentation of mutation status for B-type Raf
proto-oncogene (BRAF) and neuroblastoma ras viral oncogene homolog (NRAS)
- Participants must have experienced radiographically documented progressive disease on
or after the most recent therapy
Exclusion Criteria:
- An active, known or suspected autoimmune disease
- Conditions requiring systemic treatment with either corticosteroids within 14 days or
other immunosuppressive medications within 30 days of the first dose of study
treatment
- Current or recent gastrointestinal disease or gastrointestinal surgery that could
impact the absorption of study drug
- Untreated central nervous system (CNS) metastases or leptomeningeal metastasis
Other protocol-defined inclusion/exclusion criteria apply
Active, Not Recruiting
